Format

Send to:

Choose Destination

Links from GEO Profiles

Full record GDS4979

Lapatinib effect on lapatinib-resistant ErbB2-positive cell line: dose response

Analysis of lapatinib-resistant ErbB2-positive cells treated with 0.1 or 1 uM lapatinib. Lapatinib is an EGFR/ErbB2 inhibitor used to treat ErbB2‚Äźpositive advanced or metastatic breast cancer. Results provide insight into the mechanisms underlying the development of resistance to lapatinib.
Organism:
Homo sapiens
Type:
Expression profiling by array, count, 2 cell type, 3 dose sets
Platform:
GPL6947
Series:
GSE38376
18 Samples
Download data

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center